FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2058605806> ?p ?o ?g. }

• W2058605806 endingPage "401" @default.
• W2058605806 startingPage "395" @default.
• W2058605806 abstract "Thalidomide was developed in the 1950s as a sedative drug and withdrawn in 1961 because of its teratogenic effects, but has been rediscovered as an immuno-modifying drug. It has been administered successfully for the treatment of erythema nodosum leprosum, aphthous ulceration in HIV disease, inflammatory bowel diseases, and multiple myeloma. So far, investigations into the mode of action of thalidomide have focused on lymphocytes and vascular endothelial cells and have shown that this agent inhibits the production of tumor necrosis factor (TNF)-alpha and is an inhibitor of tumor angiogenesis. Recently, other immunological effects of this drug have been gaining attention, including attenuation of neutrophil activation and inhibition of myelo-proliferative responses. In autoimmune diseases, inflammation is characterized by an influx of granulocytes, and the association of granulocytes with gastrointestinal ulcer formation or rheumatic arthritis has been well documented. The suppressive effect of thalidomide on the activation of the nuclear transcription factor NF-(kappa)B may explain these effects of thalidomide. NF-(kappa)B is retained in the cytoplasm with I(kappa)B(alpha), and is activated by a wide variety of inflammatory stimuli including TNF, IL-1 and endotoxin followed by its translocation to the nucleus. Constitutive activation of NF-(kappa)B has been detected in various inflammatory diseases, while angiogenesis and organogenesis also require NF-(kappa)B activation. Thalidomide, on the other hand, has been shown to selectively suppress NF-(kappa)B activation induced by inflammatory mediators. NF-(kappa)B is known to be located downstream of proliferative and/or survival signaling induced by growth factors, which regulate anti-apoptotic genes. Myeloid cells in vitro, however, have been found to proceed to apoptosis as the result of the treatment with thalidomide and subsequent inactivation of NF-(kappa)B. These findings are consistent with clinical symptoms that showed the recovery from leukocytosis and/or neutrophilia after the administration of thalidomide. These findings shed new light on the anti-inflammatory properties of thalidomide and suggested that they may inhibit granulocyte-mediated tissue injury." @default.
• W2058605806 created "2016-06-24" @default.
• W2058605806 creator A5043103166 @default.
• W2058605806 creator A5058935668 @default.
• W2058605806 creator A5065591292 @default.
• W2058605806 creator A5077406348 @default.
• W2058605806 date "2005-02-01" @default.
• W2058605806 modified "2023-09-26" @default.
• W2058605806 title "Thalidomide as an Immunotherapeutic Agent: The Effects on Neutrophil- Mediated Inflammation" @default.
• W2058605806 cites W109843847 @default.
• W2058605806 cites W114205036 @default.
• W2058605806 cites W123664864 @default.
• W2058605806 cites W150089292 @default.
• W2058605806 cites W1501709778 @default.
• W2058605806 cites W1528368632 @default.
• W2058605806 cites W1568605582 @default.
• W2058605806 cites W1568733499 @default.
• W2058605806 cites W1595204255 @default.
• W2058605806 cites W1852641270 @default.
• W2058605806 cites W1877370095 @default.
• W2058605806 cites W1938023575 @default.
• W2058605806 cites W1982057903 @default.
• W2058605806 cites W1986659879 @default.
• W2058605806 cites W1994666459 @default.
• W2058605806 cites W1997317029 @default.
• W2058605806 cites W1998478088 @default.
• W2058605806 cites W2004146251 @default.
• W2058605806 cites W2009334762 @default.
• W2058605806 cites W2010002627 @default.
• W2058605806 cites W2026519817 @default.
• W2058605806 cites W2027042060 @default.
• W2058605806 cites W2028705933 @default.
• W2058605806 cites W2032468601 @default.
• W2058605806 cites W2034229930 @default.
• W2058605806 cites W2034603447 @default.
• W2058605806 cites W2036926929 @default.
• W2058605806 cites W2044240158 @default.
• W2058605806 cites W2046285825 @default.
• W2058605806 cites W2053305914 @default.
• W2058605806 cites W2054742645 @default.
• W2058605806 cites W2066936999 @default.
• W2058605806 cites W2067679507 @default.
• W2058605806 cites W2073819064 @default.
• W2058605806 cites W2075017432 @default.
• W2058605806 cites W2081704353 @default.
• W2058605806 cites W2082533672 @default.
• W2058605806 cites W2084633989 @default.
• W2058605806 cites W2109330502 @default.
• W2058605806 cites W2110995887 @default.
• W2058605806 cites W2122596233 @default.
• W2058605806 cites W2133986577 @default.
• W2058605806 cites W2142118306 @default.
• W2058605806 cites W2142149038 @default.
• W2058605806 cites W2144531125 @default.
• W2058605806 cites W2153987375 @default.
• W2058605806 cites W2158414271 @default.
• W2058605806 cites W2158541167 @default.
• W2058605806 cites W2159746652 @default.
• W2058605806 cites W2162559503 @default.
• W2058605806 cites W2163579392 @default.
• W2058605806 cites W2166229540 @default.
• W2058605806 cites W2175761939 @default.
• W2058605806 cites W2316160054 @default.
• W2058605806 cites W2317767189 @default.
• W2058605806 cites W2331176038 @default.
• W2058605806 cites W2338946788 @default.
• W2058605806 cites W2409257472 @default.
• W2058605806 cites W2417290875 @default.
• W2058605806 cites W2422103189 @default.
• W2058605806 cites W3024815325 @default.
• W2058605806 cites W327263834 @default.
• W2058605806 cites W93284168 @default.
• W2058605806 cites W2072796605 @default.
• W2058605806 doi "https://doi.org/10.2174/1381612053382179" @default.
• W2058605806 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15723633" @default.
• W2058605806 hasPublicationYear "2005" @default.
• W2058605806 type Work @default.
• W2058605806 sameAs 2058605806 @default.
• W2058605806 citedByCount "40" @default.
• W2058605806 countsByYear W20586058062012 @default.
• W2058605806 countsByYear W20586058062013 @default.
• W2058605806 countsByYear W20586058062014 @default.
• W2058605806 countsByYear W20586058062015 @default.
• W2058605806 countsByYear W20586058062017 @default.
• W2058605806 countsByYear W20586058062019 @default.
• W2058605806 countsByYear W20586058062020 @default.
• W2058605806 countsByYear W20586058062021 @default.
• W2058605806 countsByYear W20586058062022 @default.
• W2058605806 countsByYear W20586058062023 @default.
• W2058605806 crossrefType "journal-article" @default.
• W2058605806 hasAuthorship W2058605806A5043103166 @default.
• W2058605806 hasAuthorship W2058605806A5058935668 @default.
• W2058605806 hasAuthorship W2058605806A5065591292 @default.
• W2058605806 hasAuthorship W2058605806A5077406348 @default.
• W2058605806 hasConcept C17991360 @default.
• W2058605806 hasConcept C203014093 @default.
• W2058605806 hasConcept C2776246508 @default.
• W2058605806 hasConcept C2776364478 @default.

• next